Document text
Principal Investigator: John Damon Chodera
Organization: SLOAN-KETTERING INST CAN RESEARCH
Fiscal Year: 2022
Award: $7,107,143
Funding agency: National Institute of Allergy and Infectious Diseases
PROJECT SUMMARY / ABSTRACT - Administrative Core
The AI-driven Structure-enabled Antiviral Platform (ASAP) AViDD Center is organized as a distributed
antiviral discovery effort that will produce---in addition to three Investigational New Drug (IND) applications---a
robust pipeline of open science data and reagents to enable global structure-based antiviral drug discovery.
Research Projects are organized as the sequential stages of a structure-enabled discovery pipeline, supported
by Scientific Cores, with well-coordinated handoffs between Projects essential to rapid progression of
discovery programs. The goal of the Administrative Core is to coordinate and support these activities, aid
efficient execution of Research Projects, coordinate strategic and timely handoff of discovery programs
between Projects as campaigns progress through sequential stages of the discovery pipeline, oversee efficient
execution of Scientific Cores supporting these efforts, and assist in the rapid dissemination of all scientific
output to the global antiviral discovery community. Administrative Core leadership mirrors the overall ASAP
AViDD Center Leadership, consisting of three investigators with a track record of effective collaboration as core
investigators of the COVID Moonshot project that succeeded in delivering a SARS-CoV-2 oral Mpro antiviral
into preclinical studies in 18 months: Core Lead John Chodera (MSKCC), co-I Alpha Lee (PostEra), and co-I
Ben Perry (DNDi), each overseeing a subset of activities. An experienced Administrative Director will
oversee the day-to-day operations of ASAP, its finances, and scientific communications within the center, with
NIAID, and externally; a Project Coordinator will handle delegated operations tasks, meeting coordination,
subaward management, and overseeing contract research organizations (CROs). A Developmental Project
award program will be established to enable new technologies to rapidly be integrated into Center Projects or
in-depth investigation of new resistance-robust target disease biology, and a Mentored Project award program
will enable the recruitment of interdisciplinary scientists to the field of antiviral discovery. A five-member
Scientific Advisory Board (SAB) will be recruited that will actively participate in Center Quarterly meetings,
provide critical input into go/no-go decisions for promoting discovery campaigns to subsequent projects,
provide feedback on Center progress, and select Developmental and Mentored Project Awardees. The
Administrative Core will ensure that all Center operations are open and transparent, adherent to our core open
science philosophy for accelerating global antiviral discovery.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Antiviral Agents><Antiviral Drugs><Antivirals><Award><Biology><COVID><COVID-19 virus><COVID19 virus><CoV disease><CoV-2><CoV2><Collaborations><Communication><Communities><Complement><Complement Proteins><Complex><Data><Decision Making><Development><Disease><Disorder><Elements><Ensure><Feedback><Funding><Generations><Goals><Investigation><Investigational New Drug Application><Investigators><Lead><Leadership><Link><MSKCC><Memorial Sloan-Kettering Cancer Center><Mentors><Mission><NIAID><National Institute of Allergy and Infectious Disease><Oral><Output><Pb element><Phase><Philosophy><Productivity><R-Series Research Projects><R01 Mechanism><R01 Program><Reagent><Refractory><Research><Research Contracts><Research Grants><Research Personnel><Research Project Grants><Research Projects><Researchers><Resistance><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Structure><Time><Translations><Work><Wuhan coronavirus><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><base><clinical translation><corona virus disease><coronavirus disease><coronavirus disease 2019 virus><coronavirus disease-19 virus><dashboard><data infrastructure><data resource><design><designing><developmental><drug discovery><experience><hCoV19><heavy metal Pb><heavy metal lead><industrial partnership><industry partner><industry partnership><innovate><innovation><innovative><lead optimization><meetings><member><nCoV2><new technology><novel technologies><open data><open science><open-source data><operation><pre-clinical development><pre-clinical study><preclinical development><preclinical study><programs><recruit><resilience><resistant>